Combined in Vitro-in Silico Approach to Predict Deposition and Pharmacokinetics of Budesonide Dry Powder Inhalers

In Vitro Estimation of Tracheobronchial and Alveolar Doses Using Filters

“…FIGURE 5 | Comparison of amounts predicted to deposit in the tracheobronchial (TB) and alveolar regions using NGI impactor data combined with in silico regional deposition modeling (Javaheri et al, 2013) aerosols Ruzycki et al (2020) found the transverse position with the Alberta Idealized Throat improved agreement with in vivo extrathoracic deposition data.…”

“…By a similar argument, in some cases it may also be useful to discriminate between the tracheobronchial versus alveolar components of the total lung dose. Until recently, the simplest in vitro procedure for separating the lung dose into its morphological components was to measure the aerosol size distribution, typically using multistage cascade impaction, and input this into a computer model that provides estimates of regional lung deposition for the given particle size distribution and chosen inhalation pattern (e.g., Ruzycki et al, 2020;Miller et al, 2021). This labor-intensive task is complicated by the need for a mixing inlet when using realistic breathing patterns.…”

Suboptimal Inspiratory Flow Rates With Passive Dry Powder Inhalers: Big Issue or Overstated Problem?

“…If differences in TLD are to be relied upon, it is preferred that these measurements come from in vivo clinical studies (i.e., imaging or charcoal block pharmacokinetics methods). Alternatively anatomical throat models (e.g., the Alberta Idealized Throat, AIT), particularly when using realistic inspiratory flow profiles, have demonstrated good in vitro/in vivo correlations (Zhang et al, 2007;Byron et al, 2010;Delvadia et al, 2012;Olsson et al, 2013;Finlay and Martin, 2015;Weers et al, 2015;Ruzycki et al, 2019;Newman and Chan, 2020;Ruzycki et al, 2020). The last choice for estimates of TLD should be cascade impactors.…”